Evidence map›Paper›PMID 39565905›Full record

Trial reportEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery2024

Seven-year outcomes after surgical aortic valve replacement with a stented bovine pericardial bioprosthesis in over 1100 patients: a prospective multicentre analysis.

Joseph F Sabik, Vivek Rao, Francois Dagenais, Michael G Moront, Michael J Reardon, Himanshu J Patel, Jae K Oh, Shinichi Fukuhara, Louis Labrousse, Ralf Günzinger and 5 more

Abstract readClinical TrialMulticenter Study
In one paragraph

Trial report in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Joseph F SabikDepartment of Surgery, University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Vivek RaoPeter Munk Cardiac Centre, Toronto General Hospital, Toronto, ON, Canada.ORCID 0000-0003-1920-0937
Francois DagenaisCardiac Surgery Service, Quebec Heart and Lung Institute, Quebec, QC, Canada.
Michael G MorontDepartment of Cardiothoracic Surgery, ProMedica Toledo Hospital, Toledo, OH, USA.
Michael J ReardonDepartment of Cardiovascular Surgery and Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.ORCID 0000-0002-2880-6132
Himanshu J PatelDepartment of Cardiac Surgery, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-7639-2416
Jae K OhDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Shinichi FukuharaDepartment of Cardiac Surgery, University of Michigan, Ann Arbor, MI, USA.
Louis LabrousseMedico-Surgical Department of Valvulopathies, Bordeaux Heart University Hospital, Bordeaux-Pessac, France.ORCID 0000-0001-8542-9049
Ralf GünzingerDepartment of Cardiovascular Surgery, Institute Insure, German Heart Center Munich, School of Medicine & Health, Technical University of Munich, Munich, Germany.
Kamran BaigCardiovascular Department, Guys & St Thomas NHS Foundation Trust-St Thomas Hospital, London, UK.
Saki ItoDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-7076-2340
Tianhua WuClinical Research and Medical Science, Cardiac Surgery, Medtronic, Mounds View, MN, USA.
Robert J M KlautzDepartment of Cardiothoracic Surgery, Leiden University Medical Center, Leiden, The Netherlands.
PERIGON Investigators

Funding

Medtronic
6 · The paper itself

Abstract

objectivesSafety, efficacy and durability are important considerations when selecting a bioprosthesis for aortic valve replacement (AVR). This study assessed 7-year clinical outcomes and haemodynamic performance of the Avalus bioprosthesis.

methodsPatients indicated for surgical AVR were enrolled in this prospective, nonrandomized trial, conducted across 39 sites globally. The primary end-point of this analysis was freedom from surgical explant or percutaneous valve-in-valve reintervention due to structural valve deterioration (SVD) at 7 years of follow-up, determined using Kaplan-Meier (KM) analysis. We also evaluated a composite end-point of SVD and/or severe haemodynamic dysfunction requiring reintervention. Survival, valve-related safety events and haemodynamic performance were assessed. Deaths and safety events were adjudicated by an independent clinical events committee.

resultsA total of 1132 patients underwent surgical AVR. Mean age was 70 years; 854 patients (75%) were men. The mean STS risk of mortality was 2.0 ± 1.4%, and 659 patients (58%) had a New York Heart Association classification of I/II. One or more concomitant procedures were performed in 577 patients (51%). At 7 years, the Kaplan-Meier rate of freedom from SVD/severe haemodynamic dysfunction requiring reintervention was 1.2% (0.5-2.5%) with no cases adjudicated as SVD. The survival rate was 82.6% (79.5-85.0%). The KM event rate was 5.7% (4.3-7.7%) for reintervention, 6.3% (4.9-8.3%) for endocarditis and 0.4% (0.1-1.1%) for valve thrombosis. Mean aortic gradient, dimensionless velocity index and effective orifice area were 13.8 ± 5.9 mmHg, 0.42 ± 0.09 and 1.99 ± 0.53 cm2, respectively.

conclusionsThis analysis demonstrated excellent durability of the Avalus valve with good clinical outcomes and stable haemodynamic performance through 7 years of follow-up.

Indexed as

Aortic ValveBioprosthesisHeart Valve ProsthesisHeart Valve Prosthesis ImplantationPericardiumStentsAgedAged, 80 and overAnimalsCattleFemaleFollow-Up StudiesHemodynamicsHumansMaleMiddle AgedDurabilityHemodynamic performanceSurgical aortic valve replacement

Identifiers

PMID39565905
PMCPMC11742136

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.